XOMA Receives Orphan Drug Designation in the European Union for XOMA 358 for Treatment of Congenital Hyperinsulinism
20 juil. 2016 09h00 HE
|
XOMA Corporation
XOMA 358 previously secured Orphan Drug Designation from the FDA for the treatment of Congenital Hyperinsulinism (CHI)Phase 2 clinical studies currently enrolling patients with CHI in the United...
XOMA to Present at the Cantor Fitzgerald Healthcare Conference
05 juil. 2016 14h05 HE
|
XOMA Corporation
BERKELEY, Calif., July 05, 2016 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, announced today that Dr. Paul Rubin, the...
XOMA to Present at the Jefferies Global Healthcare Conference
02 juin 2016 13h48 HE
|
XOMA Corporation
BERKELEY, Calif., June 02, 2016 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, announced today that John Varian, the...
XOMA Reports First Quarter 2016 Operational Achievements and Financial Results
04 mai 2016 16h01 HE
|
XOMA Corporation
BERKELEY, Calif., May 04, 2016 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, today announced recent operational...
XOMA Reports Fourth Quarter and Full-Year 2015 Financial Results
09 mars 2016 16h01 HE
|
XOMA Corporation
BERKELEY, Calif., March 09, 2016 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, today reported the completion of its...
XOMA to Present at the Cowen & Company Health Care Conference
02 mars 2016 13h30 HE
|
XOMA Corporation
BERKELEY, Calif., March 02, 2016 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, announced today Paul Rubin, the Company’s...
XOMA to Announce Fourth Quarter and Full Year 2015 Financial Results and Host Webcast on March 9
24 févr. 2016 13h28 HE
|
XOMA Corporation
BERKELEY, Calif., Feb. 24, 2016 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of antibody therapeutics, announced the Company will host a conference...